about
Immunogenic targets for specific immunotherapy in multiple myelomaCharacterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell deathShear flow-induced formation of tubular cell protrusions in multiple myeloma cells.Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.MicroRNA: important player in the pathobiology of multiple myelomaThe miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myelomaIdentification of agents that promote endoplasmic reticulum stress using an assay that monitors luciferase secretion.Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy.A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysisLenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.Association of response endpoints with survival outcomes in multiple myeloma.Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma.Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways.The Prognostic Significance of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Patients With Multiple Myeloma.Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma.Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myelomaThe polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains.
P2860
Q26859007-F1A943C6-BE52-47AD-BDC8-321D583175D0Q28482928-B5C6179E-1CD9-4186-9F47-873290B2B663Q30501430-E17A7B0A-FB19-462C-B92D-60756023EF57Q33411277-64174155-4FC3-45B3-9193-966EA6449FD6Q33415759-7418B578-6870-4568-B7AD-077E9750CECBQ33602593-3D3FF8B9-07EC-492E-95E6-8A2C0CE9ED73Q33786861-34FDF015-BB6D-4A75-BE50-2408F3915970Q33838260-151B807E-CB51-4C8B-B8D2-95A766BA6CA9Q35076504-D9D19433-E0FA-473E-B76C-0F24F60400B3Q35846167-C7662893-B85E-433B-8BB8-99C8B2158A5AQ37375516-55A6C236-33C8-4E45-9780-22534CFEAC09Q37515416-662EB5A7-3DA7-4B0B-B122-3D638232B277Q37851855-E57C0A2B-61D8-41AD-A800-4727A3215B23Q38122624-08A2F83C-95CF-4F77-8B72-43B47D394670Q38154927-142ECC7C-1258-491B-955B-80299E67596DQ38526452-8CF86927-3350-4AE9-B1C7-BA91EC739FE0Q38676278-18DEBF96-B558-4498-A9B9-0D56DDE80682Q38848083-4DEE1C1E-7BD7-432C-A54B-769D8F7AD610Q39527323-DCAD3DB2-E7D7-4609-88FD-0C9EB1FE0513Q42287234-9CD7169C-5192-4FA4-B657-AAD8BD7BECFEQ47101382-C17AE919-DD69-4728-8DCD-BAB40A72221C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Multiple myeloma - current issues and controversies.
@en
Multiple myeloma - current issues and controversies.
@nl
type
label
Multiple myeloma - current issues and controversies.
@en
Multiple myeloma - current issues and controversies.
@nl
prefLabel
Multiple myeloma - current issues and controversies.
@en
Multiple myeloma - current issues and controversies.
@nl
P1476
Multiple myeloma - current issues and controversies.
@en
P2093
Shaji Kumar
P356
10.1016/S0305-7372(10)70006-2
P478
36 Suppl 2
P577
2010-05-01T00:00:00Z